Parkman Healthcare Partners LLC lifted its holdings in shares of Imago BioSciences, Inc. (NASDAQ:IMGO – Get Rating) by 27.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 139,751 shares of the company's stock after purchasing an additional 29,751 shares during the quarter. Parkman Healthcare Partners LLC's holdings in Imago BioSciences were worth $2,693,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently modified their holdings of the business. Vanguard Group Inc. grew its holdings in shares of Imago BioSciences by 68.8% during the first quarter. Vanguard Group Inc. now owns 793,101 shares of the company's stock worth $15,283,000 after purchasing an additional 323,376 shares in the last quarter. BlackRock Inc. lifted its position in Imago BioSciences by 146.2% in the 1st quarter. BlackRock Inc. now owns 3,290,894 shares of the company's stock worth $63,415,000 after buying an additional 1,954,112 shares during the last quarter. Rhumbline Advisers bought a new stake in Imago BioSciences in the 1st quarter worth approximately $345,000. Metropolitan Life Insurance Co NY bought a new stake in Imago BioSciences in the 1st quarter worth approximately $28,000. Finally, MetLife Investment Management LLC bought a new stake in Imago BioSciences in the first quarter valued at approximately $242,000. Hedge funds and other institutional investors own 99.50% of the company's stock.
Get Imago BioSciences alerts:Insider Transactions at Imago BioSciences
In other news, insider Jennifer Peppe sold 5,598 shares of the stock in a transaction on Monday, August 15th. The stock was sold at an average price of $19.41, for a total value of $108,657.18. Following the sale, the insider now directly owns 148,809 shares of the company's stock, valued at $2,888,382.69. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Over the last three months, insiders have sold 8,168 shares of company stock valued at $155,402. Insiders own 14.90% of the company's stock.
Analyst Ratings Changes
Separately, HC Wainwright reduced their target price on Imago BioSciences from $36.00 to $35.00 and set a "buy" rating on the stock in a research note on Tuesday, August 16th.Imago BioSciences Price Performance
NASDAQ IMGO opened at $16.77 on Friday. Imago BioSciences, Inc. has a 12 month low of $11.56 and a 12 month high of $30.21. The stock's fifty day moving average price is $16.32 and its 200-day moving average price is $17.09.
About Imago BioSciences
(Get Rating)
Imago BioSciences, Inc, a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera.
See Also
- Get a free copy of the StockNews.com research report on Imago BioSciences (IMGO)
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- Are These Green Energy Companies Right For Your Portfolio?
Want to see what other hedge funds are holding IMGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Imago BioSciences, Inc. (NASDAQ:IMGO – Get Rating).
Receive News & Ratings for Imago BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imago BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.